Clinical Trial Update: A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 window trial evaluating the immunological effects of avelumab and aspirin in triple-negative breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Aspirin (Aspirin)
• BAVENCIO (AVELUMAB)

Snippet

Sponsor: The Christie NHS Foundation Trust | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN